Prospective Observational Trial to Evaluate Quality of Life After Stereotactic Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma

Recruiting Observational Study
Hepatocellular Cancer Quality of Life Stereotactic Body Radiation Therapy Observational
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
100 (estimated)
Sponsor
Ludwig-Maximilians - University of Munich · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Prospective single arm, single center observational study to evaluate Quality of Life (Qol) after stereotactic body radiotherapy for patients with hepatocellular cancer. Patients will receive work-up, treatment and follow-up exclusively as routinely done except additional quality of life measurements. Qol will be measured by standardized and validated EORTC questionaires at different time points d…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * histologically or radiologically proven hepatocellular carcinoma * 1-3 lesions suitable for stereotactic radiation therapy * indication for SBRT according to multidisciplinary board evaluation * age \>= 18 years * written informed consent for study participation * mental and v…
Contacts

Falk Roeder, MD

+49 89 4400 73729

Falk.Roeder@med.uni-muenchen.de

CONTACT

Sabine Gerum, MD

+49 89 4400 73729

Sabine.Gerum@med.uni-muenchen.de

CONTACT